Every material Form 8-K Silexion Therapeutics Corp has filed with the SEC since November 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Silexion Therapeutics, a Cayman Islands company trading on Nasdaq as SLXN, announced a 1-for-24 reverse share split of its ordinary shares. Split-adjusted trading begins at market open on November 11, 2026, and the company says the split is intended to help it regain compliance with Nasdaq's minimum bid price requirement.
Every 24 ordinary shares will be automatically combined into one share, with the par value increasing from $0.135 to $3.24 per share
Split-adjusted trading begins on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker SLXN, with the split effective after market close on November 10, 2026
No fractional shares will be issued; DTC participants entitled to fractions will receive a rounded-up whole share, and shareholders need not take action
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Silexion Therapeutics Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →